Threshold halts lung cancer study

Threshold Pharmaceuticals has halted a Phase II trial of glufosfamide for small cell lung cancer after a Phase II interim analysis found that patients weren't responding to the drug. Of the 21 patients enrolled, only one had a response to the treatment; if three or more patients had results, the trial would have continued. Glufosfamide is also in Phase III trials for pancreatic cancer and Phase II for ovarian cancer.

We are disappointed in the study results. While we recognize that response is not a perfect surrogate for survival, the low response rate indicates that glufosfamide is not sufficiently effective as a single agent for patients with small cell lung cancer," said Barry Selick, Ph.D., chief executive officer of Threshold.

- see Threshold's release for more

Suggested Articles

Inovio CEO J. Joseph Kim is undeterred by short sellers and other detractors who doubt his company can shuttle a COVID-19 DNA vaccine to market.

Adding entinostat to hormone therapy did not help patients with HR-positive, HER2-negative breast cancer live longer.

The data add to the evidence in support of the IL-6 drug ahead of a FDA decision to approve it in a rare disease served by Alexion’s Soliris.